Research areas are:
The main objective is the development of new methodologies for the investigation of biomolecular structures, interactions, and dynamics.
We are focusing on investigations of the biomolecular structures and interactions and their relationship with physiological functions, diseases and therapies.
The next objective is the production of pure and homogeneous proteins for the structural analysis and production of monoclonal antibodies, with emphasis on the quality of the antigen-antibody selection. The result is a selection of binding molecules from synthetic DNA libraries for diagnostic and therapeutic use.
Axon Neuroscience is a clinical-stage biotech company developing disease-modifying immunotherapeutics for Alzheimer's disease and Frontotemporal lobar degeneration. Ground-breaking discoveries in Alzheimer’s disease research made by AXON Neuroscience enabled the company to create a therapeutic platform of global importance. The target products of strategic importance in this platform are revolutionary therapeutic candidate vaccines for the treatment of Alzheimer's disease and Frontotemporal lobar degeneration. AXON Neuroscience has developed unique animal models that reproduce Alzheimer’s disease and allow for a swift and effective pre-clinical validation of the efficacy of new therapeutics and pre-clinical evaluation of diagnostic tools. Strategically targeted research and development enable AXON Neuroscience to prepare for future production of an extensive assortment of disease modifying pharmaceuticals and diagnostic methods for Alzheimer’s disease.
FutureNeuro is the SFI Research Centre for Chronic and Rare Neurological Diseases, hosted by RCSI.
Funded by Science Foundation Ireland and industry, we are the national centre dedicated to brain research. We connect national and multinational industry with key academics and clinicians based in our leading hospitals to provide diagnostic, therapeutic and eHealth solutions. Our projects with industry partners will bring diagnostic supports to market, a pipeline of new drugs, and connected health solutions that enable patients to monitor and report their health better than ever before.
Initially focusing on Epilepsy and Motor Neuron Disease, we build rapidly to help transform the lives of the approximately 800,000 people affected by neurological disorders in Ireland.
Research areas are:
In the early years the Mehl lab focused on optimizing the tools of Genetic Code Expansion for robustly expressing proteins with site-specifically incorporated non-canonical amino acids that have many applications as spectroscopic probes, protein crosslinkers, post-translational modifications and bioorthogonal ligations. This powerful technology has been developed by many labs in the world for incorporation of hundreds of amino acids into many different organisms and can be overwhelming to non-experts. To provide greater access to this technology and foster its diverse use we have started the worlds first Unnatural Protein Facility at Oregon State University.
In the later years the Mehl lab has combined the advances of Genetic Code Expansion with materials and oxidative stress. The ability to site-specifically alter any protein with polymers, chemically reactive groups and oxidative damage provides our lab unique control over construction of protein in or on materials and study of oxidative stress diseases.
Our scientific interest is focused on the study of signaling pathways by post-translational modifications (phosphorylations, acetylations and others) in proteins using molecular, cellular and computational biology methods. Our study material is human and mouse cells, normal and pathological, the process of differentiation of adult mesenchymal stem cells and cell reprogramming.
Several of our lines of research focus on the master regulator of one of the most abundant post-translational modifications in the cell, phosphorylation. Said regulator is constituted by the family of proteins 14-3-3, which bind phosphorylated proteins in specific serines and threonines, located mainly in disordered regions. The 14-3-3 proteins in turn are regulated by other post-translational modifications, such as acetylation, which constitutes a regulation of regulators and establishes a cross-talk between different protein modifications. This makes the "language" used by the cell in signaling networks more complex and specific.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 873127 – InterTAU.
This websiter reflects only the author's view and the Research Executive Agency (REA) is not responsible for any use that may be made of the information it contains.